Comment from Zyla Life Sciences

Summary: Zyla Life Sciences opposes the nomination of bulk indomethacin to the FDA's 503B Bulks List, arguing that there is no clinical need for compounding it. The company contends that existing FDA-approved products can meet patient needs and highlights safety concerns regarding the manufacturing process of compounded suppositories.